Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Mischoulon, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by David Mischoulon and A. Evins.
Connection Strength

0.495
  1. Schuster RM, Pachas GN, Stoeckel L, Cather C, Nadal M, Mischoulon D, Schoenfeld DA, Zhang H, Ulysse C, Dodds EB, Sobolewski S, Hudziak V, Hanly A, Fava M, Evins AE. Phase IIb Trial of an a7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. J Clin Psychopharmacol. 2018 Aug; 38(4):307-316.
    View in: PubMed
    Score: 0.216
  2. Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P, Fava M, Mischoulon D. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012 Dec; 32(6):787-96.
    View in: PubMed
    Score: 0.146
  3. Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011 Oct; 31(5):597-602.
    View in: PubMed
    Score: 0.134
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.